Celgene International SA rl, a wholly owned subsidiary of Celgene Corporation , today announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANEA in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. For the first time in this disease, the Italian Medicines Agency has recognised the important innovation that ABRAXANE brings as a therapeutic treatment for pancreatic cancer.